Pharminent

New guidelines to make China a more drug-friendly market

CFDA announces draft guidelines that would allow Phase I trials in China to encourage simultaneous development alongside global trials. http://www.biopharmadive.com/news/china-drug-trials-manufacturing-generics-cfda/439487/

Filed under: Emerging Markets